Dr. Robert Block, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers New Jersey Medical School (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 44
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Rutgers New Jersey Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NY license 232926
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- F F Thompson Hospital Canandaigua, NY
Medical groups
- Cardiology Clinical Group (148 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 44
- Services billed
- 57
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 34 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Repatha Sureclick (evolocumab) Other prescribers in Rochester, NY | 466 |
| Ezetimibe Other prescribers in Rochester, NY | 357 |
| Praluent Pen (alirocumab) Other prescribers in Rochester, NY | 250 |
| Rosuvastatin Calcium Other prescribers in Rochester, NY | 199 |
| Atorvastatin Calcium Other prescribers in Rochester, NY | 70 |
| Amlodipine Besylate Other prescribers in Rochester, NY | 43 |
| Nexletol (bempedoic acid) | 31 |
| Vascepa (icosapent ethyl) Other prescribers in Rochester, NY | 28 |
| Fenofibrate (fenofibrate nanocrystallized) Other prescribers in Rochester, NY | 26 |
| Icosapent Ethyl Other prescribers in Rochester, NY | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $3,718 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $3,718 |
|---|
| Consulting Fee | $3,604 |
|---|---|
| Food and Beverage | $114 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee EVKEEZA · CARDIOVASCULAR AND METABOLIC | $2,253 |
| Regeneron Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee EVKEEZA · CARDIOVASCULAR AND METABOLIC | $1,352 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $95,753 in research payments for these studies, mostly to the institutions running them.
- A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
Novartis Pharmaceuticals Corporation - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - Study name not reported
Ionis Pharmaceuticals, Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.